Immuno-Oncology Overview 2017: CAR-T Cell Therapy Early Clinical Results are Extremely Promising – ResearchAndMarkets.com

DUBLIN–()–The “Immuno-Oncology
Overview”
report has been added to ResearchAndMarkets.com’s
offering.

This is an overview of the field of immuno-oncology and the various
immuno-oncology classes. Immuno-oncology is one of the most promising
and fastest growing areas of cancer research, as well as one of the most
active areas in terms of licensing deals and acquisitions.

Highlights

  • The PD-1/PD-L1 inhibitor and TCR/CAR-T therapy drug classes lead the
    development of all immuno-oncology drugs. However, several novel
    mechanisms of action are also in early-phase development.
  • Developers of approved PD-1/PD-L1 inhibitors – Bristol-Myers Squibb,
    Merck & Co, Roche, AstraZeneca, and Pfizer – currently dominate the
    immuno-oncology field in terms of the number of ongoing, conducted,
    and planned trials.
  • Furthermore, PD-1/PD-L1 inhibitors remain a focal point of
    immuno-oncology combinations, with various types of combination
    approaches being studied.

Key Topics Covered:

  1. Executive Summary
  2. Immuno-Oncology Overview
  3. Current Status Of Immuno-Oncology Development
  4. Pd-1/Pd-L1 Inhibitors
  5. Ctla-4 Inhibitors
  6. Tcr And Car-T Therapies
  7. Ido Inhibitors
  8. Emerging Drug Classes
  9. Bristol-Myers Squibb
  10. Merck & Co
  11. Roche
  12. Astrazeneca
  13. Pfizer
  14. Immuno-Oncology Combinations
  15. Kol Survey
  16. Kol Interviews

For more information about this report visit https://www.researchandmarkets.com/research/mx83p9/immunooncology?w=4



Source link

more recommended stories

Social Media Auto Publish Powered By : XYZScripts.com
%d bloggers like this: